Companies covered: Spark Therapeutics, Inc. (NASDAQ:ONCE), Roche Holdings Ltd. (ADR) (OTCMKTS:RHHBY), Audentes Therapeutics (NASDAQ:BOLD), Novartis AG (NYSE:NVS), bluebird bio, Inc. (NASDAQ:BLUE), Novocure Ltd. (NASDAQ:NVCR), Mallinckrodt plc (NYSE:MNK), Endo International plc (NASDAQ:ENDP), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Insys Therapeutics, Inc. (NASDAQ:INSY), Johnson & Johnson (NYSE:JNJ), Recro Pharma, Inc. (NASDAQ:REPH), Flexion Therapeutics, Inc. (NASDAQ:FLXN), Galapagos NV (NASDAQ:GLPG), Amneal Pharmaceuticals (NYSE:AMRX), Indivior PLC (OTCMKTS:IZQVF), Reckitt Benckiser Group plc (OTCMKTS:RBGPF), Quick-Med Technologies Inc. (OTCMKTS:QMDT), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Oncternal Therapeutics, Inc. (NASDAQ:ONCT), RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI), BioXcel Therapeutics, Inc. (NASDAQ:BTAI), Phio Pharmaceuticals Corp. (NASDAQ:PHIO), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)
